TH Protein — Tyrosine Hydroxylase

TH Protein — Tyrosine Hydroxylase

Overview

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthetic pathway for catecholamines, catalyzing the conversion of L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine). This enzyme plays a pivotal role in the biosynthesis of [dopamine](/entities/dopamine), [norepinephrine](/entities/norepinephrine), and [epinephrine](/entities/epinephrine). In the central nervous system (CNS), TH is predominantly expressed in catecholaminergic neurons of the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), locus coeruleus, and other brain regions. The enzyme's activity is essential for maintaining dopamine levels critical for motor control, reward processing, and cognitive function. Loss of TH activity is a hallmark of Parkinson's disease (PD), where degeneration of dopaminergic neurons in the SNpc leads to characteristic motor symptoms [@leviel2010].

TH Protein — Tyrosine Hydroxylase

Overview

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthetic pathway for catecholamines, catalyzing the conversion of L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine). This enzyme plays a pivotal role in the biosynthesis of [dopamine](/entities/dopamine), [norepinephrine](/entities/norepinephrine), and [epinephrine](/entities/epinephrine). In the central nervous system (CNS), TH is predominantly expressed in catecholaminergic neurons of the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), locus coeruleus, and other brain regions. The enzyme's activity is essential for maintaining dopamine levels critical for motor control, reward processing, and cognitive function. Loss of TH activity is a hallmark of Parkinson's disease (PD), where degeneration of dopaminergic neurons in the SNpc leads to characteristic motor symptoms [@leviel2010].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Tyrosine Hydroxylase</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Tyrosine Hydroxylase</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[TH](/genes/th)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P07101](https://www.uniprot.org/uniprot/P07101)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>6HC8, 6HC9, 4XFY, 5TO1</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>58.5 kDa (per subunit)</td></tr>
<tr><td><strong>Length</strong></td><td>528 amino acids</td></tr>
<tr><td><strong>Quaternary Structure</strong></td><td>Homotetramer</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm; associated with vesicles</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Tyrosine hydroxylase family (aromatic amino acid hydroxylases)</td></tr>
<tr><td><strong>Expression</strong></td><td>High in SNpc, VTA, locus coeruleus</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">CANCER</a>, <a href="/wiki/depression" style="color:#ef9a9a">DEPRESSION</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">PARKINSON</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's Disease</a>, <a href="/wiki/tumor" style="color:#ef9a9a">TUMOR</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">183 edges</a></td>
</tr>
</table>
</div>

Structure

TH belongs to the aromatic amino acid hydroxylase family, which also includes phenylalanine hydroxylase (PAH) and tryptophan hydroxylase (TPH). The enzyme has a characteristic tetrameric quaternary structure, with each subunit capable of independent catalytic activity.

Overall Architecture

Each TH subunit comprises three major functional domains:

N-terminal Regulatory Domain (aa 1-160)
The N-terminal region contains the regulatory domain that controls enzyme activity in response to neuronal signaling. This domain contains multiple phosphorylation sites (Ser8, Ser19, Ser31, Ser40) that modulate TH activity through phosphorylation-dependent mechanisms. The regulatory domain also contains the binding site for the endogenous inhibitor dopamine, providing feedback regulation of TH activity.

Catalytic Domain (aa 161-400)
The central catalytic domain contains the active site where the hydroxylation of L-tyrosine occurs. This domain binds the pterin cofactor tetrahydrobiopterin (BH4) and the iron necessary for catalytic activity. The catalytic domain shares significant sequence homology with PAH and TPH, with conserved residues required for binding substrate, cofactor, and iron.

C-terminal Domain (aa 401-528)
The C-terminal domain contributes to tetramer formation and protein-protein interactions. This region contains sequences involved in homooligomerization and association with regulatory proteins.

Active Site Architecture

The catalytic center of TH contains:

• Iron (Fe²⁺): The essential metal cofactor required for oxygen activation and substrate hydroxylation. Iron is coordinated by conserved residues (His331, His336, Asp355, His361).
• BH4 Binding Site: Tetrahydrobiopterin binds in a pocket adjacent to the active site, providing the hydride donor for the hydroxylation reaction.
• Substrate Channel: A dedicated binding site for L-tyrosine positioned for hydroxylation at thepara position.

Oligomerization

TH functions as a homotetramer, with subunits arranged in a dimer-of-dimers configuration. Oligomerization is mediated by C-terminal interactions and is essential for enzyme stability and proper regulation. Tetramer formation can be modulated by phosphorylation and protein-protein interactions.

Normal Function in the Nervous System

Catecholamine Biosynthesis

TH catalyzes the rate-limiting step in dopamine biosynthesis:

L-Tyrosine →[TH/BH4/O₂]→ L-DOPA →[AADC]→ Dopamine →[DBH]→ Norepinephrine →[PNMT]→ Epinephrine

The reaction requires:

• Tetrahydrobiopterin (BH4): The essential pterin cofactor, synthesized by GTP cyclohydrolase (GCH1)
• Molecular oxygen (O₂): The oxygen acceptor
• Iron (Fe²⁺): Required for catalytic activity

Regulation by Phosphorylation

TH activity is dynamically regulated by phosphorylation at multiple serine residues:

Ser40 (Major Regulatory Site)
Phosphorylation at Ser40 by several kinases (PKA, CaMKII, ERK1/2, MAPKAPK2) dramatically increases TH activity (up to 10-fold). This phosphorylation reduces the Km for L-tyrosine and decreases inhibition by dopamine. Ser40 phosphorylation is the primary mechanism linking neuronal activity to catecholamine synthesis.

Ser19
Phosphorylation at Ser19, primarily by CaMKII, promotes subsequent phosphorylation at Ser40 and increases TH stability. This site also mediates binding of 14-3-3 proteins, which further stimulate TH activity.

Ser31
Phosphorylation at Ser31 by ERK1/2 provides moderate activation (approximately 2-fold increase) and may regulate TH localization within neurons.

Ser8
Phosphorylation at Ser8, by PKA or other kinases, contributes to overall activation but plays a lesser role than Ser40.

Regulation by End Products

Dopamine and other catecholamines provide feedback inhibition of TH activity through:

• Direct binding to the regulatory domain
• Competition with BH4 at the catalytic site
• Allosteric inhibition of substrate binding

Integration with Neuronal Activity

TH activity is tightly coupled to neuronal firing rates. Increased neuronal activity leads to:

• Elevated calcium influx
• Activation of calcium-dependent kinases (CaMKII)
• Increased TH phosphorylation at Ser19 and Ser40
• Enhanced dopamine synthesis to meet increased neurotransmitter demand

Role in Neurodegenerative Diseases

Parkinson's Disease

TH deficiency is a central feature of Parkinson's disease pathology:

Loss of TH in SNpc Neurons
In PD, the dopaminergic neurons of the substantia nigra pars compacta (SNpc) undergo progressive degeneration. These neurons are the primary source of TH in the brain, and their loss leads to severe reductions in striatal dopamine content. TH activity in remaining neurons is also reduced due to:

• Reduced gene expression
• Impaired phosphorylation mechanisms
• Post-translational modifications that decrease enzyme activity

TH as Biomarker
TH expression in blood and CSF is being explored as a biomarker for:

• Early PD detection
• Disease progression monitoring
• Treatment response assessment

Segawa Syndrome (Dopa-Responsive Dystonia)

Autosomal dominant mutations in the TH gene cause Segawa syndrome, also known as dopa-responsive dystonia (DRD). This disorder is characterized by:

• Childhood-onset dystonia (abnormal muscle tone)
• Parkinsonism features
• Dramatic response to L-DOPA treatment
• Diurnal fluctuation (symptoms worsen throughout the day)

TH Deficiency (Autosomal Recessive)

Rare autosomal recessive TH deficiency causes a more severe phenotype than Segawa syndrome:

• Infantile-onset progressive encephalopathy
• Severe parkinsonism
• Cognitive impairment
• Developmental delays

Alzheimer's Disease

While primarily a dopaminergic enzyme, TH is affected in AD through:

Locus Coeruleus Degeneration
The locus coeruleus (LC), the main source of norepinephrine in the brain, degenerates in AD. TH-expressing neurons in the LC are lost, leading to:

• Reduced norepinephrine levels
• Dysregulation of attention and arousal
• Enhanced neuroinflammation

Multiple System Atrophy (MSA)

In MSA, TH deficiency in striatal and cortical regions contributes to:

• Parkinsonism
• Autonomic dysfunction
• Cerebellar symptoms

Therapeutic Targeting

L-DOPA Therapy

L-DOPA (levodopa), combined with carbidopa or benserazide (peripheral DOPA decarboxylase inhibitors), remains the gold standard treatment for TH-related disorders:

Mechanism: L-DOPA bypasses the rate-limiting TH step, directly providing substrate for AADC to synthesize dopamine.

Pharmacokinetics:

• Carbidopa prevents peripheral conversion, ensuring more L-DOPA reaches the brain
• Plasma half-life: 1-3 hours
• Requires 3-4 daily dosing for continuous coverage

• Long-term use leads to motor complications (dyskinesias)
• Does not slow disease progression
• Efficacy decreases as more neurons are lost

Gene Therapy Approaches

Viral vector-mediated TH gene delivery is being developed as a potential treatment:

AAV-Mediated TH Delivery
Recombinant adeno-associated viruses (AAV) carrying the TH gene can be delivered to the striatum, where they transduce neurons to produce TH locally. This approach aims to:

• Restore dopamine synthesis in remaining neurons
• Provide more continuous dopamine replacement
• Reduce L-DOPA requirements [@kawabata2023]

• TH + AADC (complete dopamine pathway)
• TH + GTPCH1 (cofactor supply)
• TH + aromatic L-amino acid decarboxylase (AADC)

Small Molecule Activators

BH4 Supplementation
Tetrahydrobiopterin (BH4) is the essential cofactor for TH. Supplementing BH4 may enhance residual TH activity in patients with cofactor deficiency. However, BH4 does not cross the blood-brain barrier efficiently, limiting its utility.

Modulators of TH Phosphorylation
Developing compounds that enhance TH phosphorylation at activating sites (Ser40) could boost residual enzyme activity.

Neuroprotective Strategies

Enhancing TH Expression
Transcription factors that increase TH gene expression (e.g., Nurr1, Pitx3) are being explored as neuroprotective strategies.

Stabilizing TH Protein
Preventing TH degradation through autophagy or the ubiquitin-proteasome system could preserve residual enzyme activity.

Signaling and Regulation

Key Publications

See Also

• [TH Gene](/genes/th)
• [Dopamine Biosynthesis Pathway](/mechanisms/dopamine-biosynthesis)
• [Parkinson's Disease Pathogenesis](/diseases/parkinsons-disease)
• [Dopa-Responsive Dystonia](/diseases/dopa-responsive-dystonia)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Ventral Tegmental Area](/brain-regions/ventral-tegmental-area)
• [GCH1 Protein](/proteins/gch1-protein)
• [AADC Protein](/proteins/aadc-protein)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)

References